Scienture (NASDAQ:SCNX – Get Free Report) and Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.
Institutional and Insider Ownership
5.7% of Scienture shares are held by institutional investors. 19.5% of Scienture shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and target prices for Scienture and Bayer Aktiengesellschaft, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Scienture | 1 | 1 | 1 | 0 | 2.00 |
| Bayer Aktiengesellschaft | 0 | 1 | 5 | 2 | 3.12 |
Earnings & Valuation
This table compares Scienture and Bayer Aktiengesellschaft”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Scienture | $430,000.00 | 10.62 | -$41.51 million | ($52.50) | -0.05 |
| Bayer Aktiengesellschaft | $51.55 billion | 1.17 | -$4.10 billion | ($0.42) | -36.55 |
Scienture has higher earnings, but lower revenue than Bayer Aktiengesellschaft. Bayer Aktiengesellschaft is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Scienture and Bayer Aktiengesellschaft’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Scienture | N/A | -60.22% | -47.93% |
| Bayer Aktiengesellschaft | -3.12% | 16.10% | 4.27% |
Risk & Volatility
Scienture has a beta of 3.57, indicating that its stock price is 257% more volatile than the S&P 500. Comparatively, Bayer Aktiengesellschaft has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
About Scienture
Scienture is a specialty pharmaceutical company focused on developing and commercializing prescription treatments, particularly for central nervous system disorders. Its work includes advancing medicines and drug-delivery formulations intended to address patient needs in these areas. The company’s portfolio has included ZolpiMist, an FDA-approved zolpidem tartrate oral spray used to treat insomnia. Scienture has focused primarily on the U.S. pharmaceutical market.
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft is a German life sciences company headquartered in Leverkusen. Founded in 1863, it develops products and services in pharmaceuticals, consumer health and agriculture. Its Pharmaceuticals business offers prescription medicines, including treatments in areas such as cardiovascular disease, oncology, women’s health and eye care. Consumer Health sells nonprescription medicines and self-care products, with brands including Claritin, Aleve and One A Day. Through its Crop Science business, Bayer provides seeds, crop protection products and agricultural solutions for farmers.
Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.
